Patents matching “formulation”

US 11819496

Topical roflumilast formulation having improved delivery and plasma half-life

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Nov 21, 2023 · Expires Nov 16, 2043

US 11813359

Sustained release olanzapine formulations

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Nov 14, 2023 · Expires Nov 9, 2043

US 11806398

Citrate buffered VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Nov 7, 2023 · Expires Nov 2, 2043

US 11806400

Injectable ibuprofen formulation

Cumberland Pharmaceuticals Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

US 11806429

Film formulations containing dexmedetomidine and methods of producing them

BioXcel Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

US 11807868

Adeno-associated variants, formulations and methods for pulmonary delivery

4D MOLECULAR THERAPEUTICS INC. · Granted Nov 7, 2023 · Expires Nov 2, 2043

US 11793819

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Oct 24, 2023 · Expires Oct 19, 2043

US 11795180

Formulation of a pan-JAK inhibitor

Theravance Biopharma R&D IP, LLC · Granted Oct 24, 2023 · Expires Oct 19, 2043

US 11786518

Ophthalmic formulations and uses thereof

Aldeyra Therapeutics, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

US 11786598

Lipid formulations for delivery of therapeutic agents

ARBUTUS BIOPHARMA CORPORATION · Granted Oct 17, 2023 · Expires Oct 12, 2043

US 11759446

Liquid tasimelteon formulations and methods of use thereof

VANDA PHARMACEUTICALS INC. · Granted Sep 19, 2023 · Expires Sep 14, 2043

US 11752137

Ophthalmic compositions for treating ocular Demodex using lotilaner formulations

Tarsus Pharmaceuticals, Inc. · Granted Sep 12, 2023 · Expires Sep 7, 2043

US 11744816

Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

Esperion Therapeutics, Inc. · Granted Sep 5, 2023 · Expires Aug 31, 2043

US 11744800

Methods of use of emulsion formulations of an NK-1 receptor antagonist

Heron Therapeutics, Inc. · Granted Sep 5, 2023 · Expires Aug 31, 2043

US 11737983

Storage stable sincalide formulations

MAIA PHARMACEUTICALS, INC. · Granted Aug 29, 2023 · Expires Aug 24, 2043

US 11737991

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

TONIX PHARMA LIMITED · Granted Aug 29, 2023 · Expires Aug 24, 2043

US 11732024

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

US 11730740

Laureth-4 containing topical formulations

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

US 11730793

Sustained release formulations using non-aqueous emulsions

REGENERON PHARMACEUTICALS, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

US 11712475

Sustained delivery formulations of risperidone compound

Indivior UK Limited · Granted Aug 1, 2023 · Expires Jul 27, 2043

US 11707454

Topical roflumilast formulation having antifungal properties

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jul 25, 2023 · Expires Jul 20, 2043

US 11701420

Parenteral norovirus vaccine formulations

Takeda Vaccines, Inc. · Granted Jul 18, 2023 · Expires Jul 13, 2043

US 11701421

Compositions and methods for stabilizing flaviviruses with improved formulations

Takeda Vaccines, Inc. · Granted Jul 18, 2023 · Expires Jul 13, 2043

US 11690898

Adeno-associated virus Factor VIII vectors, associated viral particles and therapeutic formulations comprising the same

BIOMARIN PHARMACEUTICAL INC. · Granted Jul 4, 2023 · Expires Jun 29, 2043